Drug Trial Radar · NCT00467662
Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)
Last checked: Nov 20, 2026Latest source record: May 1, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
75
Planned (sponsor's estimate)
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Hadassah Medical OrganizationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 1, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recurrent cold sores - herpes simplex labialis (HSL) occurs in 20-40% of the US population and patient seek treatment because of the discomfort and visibility of the lesion although it is a self limiting disease. The purpose of this study is to check the safety, Efficacy and convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.
Conditions
- Reccurent Herpes Labialis
Interventions
Acyclovir 5%Drug
Docosanol 10%Drug
Superlysine gelDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reducing healing process and duration of cold sores using superlysin gel
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.